2006, Number 1
<< Back Next >>
Bol Col Mex Urol 2006; 21 (1)
Interferon alpha 2b in advanced renal cancer as monotherapy or adjuvant therapy
Vite-Velázquez EJ, Hernández OOF
Language: Spanish
References: 13
Page: 11-15
PDF size: 76.07 Kb.
ABSTRACT
Antecedents: The renal cancer advanced is resistant to radiotherapy, hormonotherapy and/or chemotherapy. Studies based on immunotherapies have shown encouraging answer. The mechanism of action of the immunotherapy is not understood.
Objective: To evaluate the survival of patients with metastatic renal-cell cancer deal with interferon alpha 2b.
Material and methods: Cases with diagnosis of metastatic renal-cell cancer between March 2003 to June 2005 were reviewed. This is a cross-sectional, retrospective, descriptive and comparative study. Two groups integrated: Group A. cases with metastatic renal-cell cancer handled with radical surgery + interferon alpha and, Group B. cases with metastatic renal-cell cancer handled with interferon alpha solely.
Results: 44% of the cases were handled with radical surgery + interferon alpha with average survival of 15.4 months, 56% cases dealt with interferon alpha with average survival of 9.4 months. There was not regression of tumor-load any case.
Conclusion: In cases with metastatic renal-cell cancer in good state of health handled with radical nephrectomy + interferon alpha 2b the survival is better than in the cases handled solely with interferon alpha 2b.
REFERENCES
Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with combination of subcutaneous interleukin 2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015.
Neri B, Doni L, Gemelli M et al. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin 2 immunotherapy for metastatic renal cell carcinoma. J Urol 2002; 168: 956-958.
Griffiths T, Mellon J. Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J 2004; 80: 320-327.
Negrier S, Escudier B, Lasset C et al. Recombinant human Interleukin-2 recombinant human Interferon Alfa 2-a, or both in metastatic renal cell carcinoma. N Engl J Med 1998; 338: 1272-1278.
Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology 1999; 13: 801-10.
Flanigan R, Salmon S, Blumenstein et al. Nephrectomy followed by interferon alfa 2b compared with interferon alfa 2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655-1659.
Krejci K, Markiewicz M, Kwon E. Immunotherapy for urological malignancies. J Urol 2004; 171: 870-876.
Zisman A, Wieder J, PAntuck A et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003; 169: 909-916.
Alatrash G, Hutson T, Molto L et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa 2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 2004; 22: 2891-2900.
Sharieff K, Duncan D, Younossi Z et al. Advances in treatment of chronic hepatitis C: pegylated interferons. Cleve Clin J Med 2002; 69: 155-159.
Wagner J, Walther M, Linehan et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999; 162: 43-45.
Jaremtchuk A, Aman E, Ponce W et al. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma. Am J Clin Oncol 2002; 25: 123-125.
Curti B. Renal cell carcinoma. JAMA 2004; 292: 97-100.